Patent application number | Description | Published |
20130072492 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS - A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof. | 03-21-2013 |
20130217695 | BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES - The present invention is directed to compounds which are inhibitors of the dipeptidyl peptidase-IV enzyme (“DP-IV inhibitors”) and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 08-22-2013 |
20150018399 | GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE - Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. | 01-15-2015 |
20150336946 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT - Novel pyridine-2-carboxamide derivatives of formula I and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included. The present invention relates to novel pyridine-2-carboxamide derivatives and salts thereof which are effective as glucokinase activating agents. Moreover, it relates to compositions containing such compounds, and methods of treatment. | 11-26-2015 |
20150336991 | NOVEL GLUCOKINASE ACTIVATOR COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT - Novel pyridine-2-carboxamide derivatives of formula I: and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are effective as glucokinase activating agents. Pharmaceutical compositions and methods of treatment are also included. | 11-26-2015 |
Patent application number | Description | Published |
20110048104 | TEST APPARATUS - A test sample is provided for testing performance of measuring and monitoring equipment for production lines, for example for foodstuffs or pharmaceuticals, and in particular, contamination monitoring equipment employing X-rays and/or metal detectors to spot foreign bodies in packaged products. The test sample may comprise a laminated card enclosing a standardised test piece such as a metal particle of specified size. The card or other sample bears at least one identification containing a barcode, readable by an optical scanner. To test the equipment, a card is placed on a product package passing through the equipment, the optical scanner reads the barcode to confirm that the correct test sample has been submitted, and the results for the test sample are recorded in a computer log. If the results do not match those expected from the particular test sample submitted, the equipment fails the test and requires recalibration or repair. | 03-03-2011 |
20150052967 | TEST APPARATUS - A test sample is provided for testing performance of measuring and monitoring equipment for production lines, for example for foodstuffs or pharmaceuticals, and in particular, contamination monitoring equipment employing X-rays and/or metal detectors to spot foreign bodies in packaged products. The test sample may comprise a laminated card enclosing a standardised test piece such as a metal particle of specified size. The card or other sample may bear at least one identification containing a barcode, readable by an optical scanner. To test the equipment, a card is placed on a product package passing through the equipment, the optical scanner reads the barcode to confirm that the correct test sample has been submitted, and the results for the test sample are recorded in a computer log. If the results do not match those expected from the particular test sample submitted, the equipment fails the test and requires recalibration or repair. | 02-26-2015 |